Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

被引：26
|
作者：
Ciuleanu, T.
Samarzjia, M.
Demidchik, Y.
Beliakouski, V.
Rancic, M.
Bentsion, D. L.
Orlov, S. V.
Schaeffier, B. A.
De Jager, R. L.
Breitz, H. B.
机构：
[1] Inst Oncol I Chiricuta, Cluj Napoca, Romania
[2] Clin Pulm Dis, Zagreb, Croatia
[3] Minsk City Clin Oncol Dispensary, Minsk, BELARUS
[4] Gomel Reg Oncol Dispensary, Gomel, BELARUS
[5] Clin Ctr Nis, Nish, Serbia
[6] Sverdiovsk Reg Oncol Ctr, Ekaterinburg, Russia
[7] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[8] Poniard Pharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7002
引用
收藏
页数：2
相关论文
共 50 条
  • [31] CABAZITAXEL (CBZ) VS TOPOTECAN (TPT) IN PATIENTS (PTS) WITH SMALL CELL LUNG CANCER (SCLC) WITH PROGRESSIVE DISEASE DURING/AFTER FIRST-LINE (1L) TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY (CTX)
    Evans, T.
    Cho, B. C.
    Udud, K.
    Fischer, J. R.
    Shepherd, F. A.
    Martinez, P.
    Ramlau, R.
    Syrigos, K. N.
    Chadjaa, M.
    Wolf, M.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S28 - S29
  • [32] Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
    Vignani, Francesca
    Tambaro, Rosa
    De Giorgi, Ugo
    Giannatempo, Patrizia
    Bimbatti, Davide
    Carella, Claudia
    Stellato, Marco
    Atzori, Francesco
    Aieta, Michele
    Masini, Cristina
    Hamzaj, Alketa
    Ermacora, Paola
    Veccia, Antonello
    Scandurra, Giuseppa
    Gamba, Teresa
    Ignazzi, Gianluca
    Pignata, Sandro
    Di Napoli, Marilena
    Lolli, Cristian
    Procopio, Giuseppe
    Pierantoni, Francesco
    Zonno, Antonia
    Santini, Daniele
    Di Maio, Massimo
    EUROPEAN UROLOGY, 2023, 83 (01) : 82 - 89
  • [33] Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
    Machiels, Jean-Pascal
    Subramanian, Somasundaram
    Ruzsa, Agnes
    Repassy, Gabor
    Lifirenko, Igor
    Flygare, Annika
    Sorensen, Per
    Nielsen, Tina
    Lisby, Steen
    Clement, Paul M. J.
    LANCET ONCOLOGY, 2011, 12 (04): : 333 - 343
  • [34] A phase 2 study of picoplatin monotherapy for patients with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum-containing chemotherapy
    Karlin, David A.
    Breitz, Hazel
    Baker, Gizelle
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S424 - S424
  • [35] A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy
    Ettinger, D. S.
    Jotte, R. M.
    Gupta, V.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian
    Paz-Ares, Luis G.
    Jiang, Haiyi
    Huang, Yifan
    Dennis, Phillip A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.
    Ciardiello, Fortunato
    Bang, Yung-Jue
    Bendell, Johanna C.
    Cervantes, Andres
    Brachmann, Rainer Karl
    Zhang, Yuting
    Raponi, Mitch
    Farin, Heinrich
    Lin, Shen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [38] A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD plus advanced ovarian cancer after response to front-line platinum-based chemotherapy.
    Gonzalez-Martin, Antonio
    Backes, Floor Jennishens
    Baumann, Klaus H.
    Chase, Dana Meredith
    Fehr, Mathias Konrad
    Coleman, Robert L.
    Freyer, Gilles
    DiSilvestro, Paul
    Lavie, Ofer
    Herzog, Thomas J.
    Lorusso, Domenica
    Moore, Kathleen N.
    Mirza, Mansoor Raza
    O'Cearbhaill, Roisin Eilish
    Vergote, Ignace
    Pothuri, Bhavana
    Balser, John
    Agarwal, Shefali
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
    Gupta, Shilpa
    Ballman, Karla V.
    Galsky, Matt D.
    Morris, Michael J.
    Sridhar, Srikala S.
    Chen, Ronald C.
    Chan, Timothy An-Thy
    Wen, Yujia
    Grivas, Petros
    Tan, Alan
    Baghaie, Shiva
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.
    Ciardiello, Fortunato
    Bang, Yung-Jue
    Bendell, Johanna C.
    Cervantes, Andres
    Dvorkin, Mikhail
    Lopez, Charles D.
    Metges, Jean-Philippe
    Sanchez, Antonio
    Calvo, Mariona
    Strickland, Andrew
    Kannourakis, George
    Muro, Kei
    Kawakami, Hisato
    Wei, Jia
    Borg, Christophe
    Mu, Song
    Zhang, Kathy
    Zhang, Maggie
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345